Wintergreen.
Wintergreen oil is mostly methyl salicylate. Rubbed into skin it gives that warming, counter-irritant feeling over tired muscles and stiff joints.
- Category
- Herb
What Wintergreen is, and what it does.
- Does it work
- It suits people who like a warming topical rub after training or a long day on their feet. If you take blood thinners or react to salicylates, check with a clinician first.
- How much to take
- No dose figure is on record for wintergreen, so we won't invent one. Topical products carry methyl salicylate at roughly 10 to 30 percent, and the oil is for external use only.
- Time to feel it
- On skin, the warmth starts within a few minutes and settles over about half an hour. There's no build-up phase to wait through.
- The first dose
- Day one is the minty tingle and warmth where you rubbed it, fading over an hour or two. It's a per-application effect from the start.
- With regular use
- Weeks of use keep it a per-application effect rather than a cumulative one. Absorption climbs with heat, wraps, large areas and exercise straight afterwards.
- How well tolerated
- Skin irritation is the usual issue. Swallowing the oil is hazardous even in small volumes, especially for children. Keep it off broken skin, and check first if you take salicylates.
- How it feels
- A sharp minty smell, then heat spreading where you applied it. On thin skin some people find it more hot than pleasant.
- The overlooked benefit
- The aroma isn't in the intact leaf. It appears only after the gaultherin glycoside is broken down, which is why old preparations soaked the leaves before distilling.
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
- Muscle and joint comfort after exertion, applied topicallyRandomised trial
- Local counter-irritant warming at the site of applicationNarrative review
- Salicylate uptake through intact skin into the bloodstreamRandomised trial
- Cyclooxygenase inhibition by the salicylic acid it releasesNarrative review
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Wintergreen oil is roughly 96 to 99 percent methyl salicylate, which esterases hydrolyse to salicylic acid after absorption, including absorption through skin. Willow bark salicin is metabolised to saligenin and then to salicylic acid. Combining them stacks two inputs to one systemic salicylate pool, and topical methyl salicylate absorbs far better than most people assume. This is the pairing most likely to produce unintended salicylate loading.
Salicylic acid derived from methyl salicylate inhibits COX-1 in platelets, cutting thromboxane A2 production. High dose EPA competes with arachidonic acid as a substrate and yields the far less aggregatory thromboxane A3. The two mechanisms are independent, so the effect on bleeding time layers. This matters most around surgery and for anyone already on an antiplatelet agent.
Ginkgolides block the PAF receptor, which is a different pathway from COX inhibition. Case reports of bleeding events with ginkgo cluster around concurrent antiplatelet use. Adding a salicylate source, including a topical one used generously, moves in the same direction. The individual contributions are modest and the stacking is the concern.
Nattokinase degrades fibrin directly and reduces plasminogen activator inhibitor activity, acting on clot breakdown rather than on platelet aggregation. Salicylate acts on the platelet side. Combined, both arms of haemostasis are affected at once. This is a reason for care rather than a formulation idea.
Garlic constituents reduce platelet aggregation in a dose related way, with the effect clearest for concentrated preparations rather than culinary amounts. Layered onto a salicylate source, the combined effect on bleeding time is larger than either alone. Surgical guidance commonly asks for garlic supplements to be stopped in advance for this reason.
Menthol disrupts stratum corneum lipid packing and increases the flux of co-applied lipophilic compounds across skin. It also produces a cooling sensation through TRPM8 activation that reinforces the perceived effect. The formulation consequence deserves stating plainly: menthol raises systemic methyl salicylate absorption, not only local delivery. That is the mechanism behind reported salicylate toxicity from heavy topical use.
Camphor appears with methyl salicylate and menthol in the conventional counter-irritant formulation, contributing its own sensory effect and modifying skin permeability. It is also independently toxic if ingested, especially in children. A product carrying all three is a formulation with three separate ingestion hazards in one bottle. Regard the pairing as formulation convention with a real storage consideration attached.
Curcumin reduces thromboxane synthesis and platelet aggregation in laboratory work, though its poor oral bioavailability limits how much of this translates. Bioavailability enhanced formulations narrow that gap. Since the two ingredients target the same use occasion, they are often taken together without either being counted. Worth noting rather than alarming.
Nothing specific on file for Wintergreen. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Wintergreen actually does.
Wintergreen oil is roughly 96 to 99 percent methyl salicylate, and one millilitre equals about 1.4 grams of salicylate, so small ingested amounts add up to a large salicylate dose, especially in children.
The oil itself isn't active until enzymes in the body convert it into salicylic acid, the compound behind both its effects and its toxicity risk.
Salicylic acid blocks an enzyme involved in inflammation signaling, and in platelets, which can't remake that enzyme, the effect lasts for the rest of that platelet's life.
Wintergreen oil absorbs through intact skin easily, and covering the area, heat, applying it over a large area, or exercising afterward all raise how much reaches the rest of the body from what's meant to be a local product.
The forms it comes in.
The studies, linked.
10 sources behind our Wintergreen verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialAlleviation of Upper Respiratory Inflammation and Associated Common Cold SymptomsClinicalTrials.gov ↗Phase 1, 157 participants, Completed
- Clinical trialA Randomized, Double-Blind, Crossover, Pilot Study to Evaluate the Safety and Efficacy of Ariva® Silver Wintergreen, a Smoking Aversive Lozenge, in Reducing Craving for a Cigarette in Daily SmokersClinicalTrials.gov ↗Phase 1, 111 participants, Completed
- Clinical trialA Randomized, Controlled, Partial-Blind, Crossover Study to Characterize the Nicotine Pharmacokinetics and Subjective Effects of Five Oral Nicotine Products Relative to Moist Smokeless Tobacco (MST) in Adult MST UsersClinicalTrials.gov ↗64 participants, Completed
- Clinical trialA Randomized, Double-Blinded, Placebo-Controlled, Crossover, Pilot Study to Evaluate the Efficacy of Ariva® Silver Wintergreen, a Smoking Aversive Lozenge, Containing Tobacco and Silver Salt - in Healthy SmokersClinicalTrials.gov ↗Phase 1, 43 participants, Completed
- Clinical trialA Randomized, Double-Blinded, Active-Controlled, Crossover, Pilot Study to Evaluate the Efficacy and Safety of Ariva® Silver Wintergreen, a Smoking Aversive Lozenge, Containing Tobacco and Silver Salt - in Healthy SmokersClinicalTrials.gov ↗Phase 1, 37 participants, Completed
- Clinical trialEffect of Flavored on!® Nicotine Pouch Products on Smoking Behaviors: a Sequential Multiple Assignment Randomized Controlled TrialClinicalTrials.gov ↗400 participants, Unknown
- Clinical trialRandomized Placebo-controlled Trial of Nicotine Pouches in SmokersClinicalTrials.gov ↗375 participants, Recruiting
- Clinical trialAn In-Clinic Confinement Study to Assess Elements of Abuse Liability of Four Modern Oral Nicotine ProductsClinicalTrials.gov ↗50 participants, Not yet recruiting
- Clinical trialAn In-Clinic Confinement Study to Assess Elements of Abuse Liability of Two Modern Oral Nicotine Pouched ProductsClinicalTrials.gov ↗40 participants, Not yet recruiting
- ClinicalTrials.gov ↗
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
Problems people have reported.
Read this carefully. These are 36 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Wintergreen is, not how risky it is. A report is not proof Wintergreen caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.